MiNK Therapeutics, Inc. (INKT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 2 Expansion 3 Platform 1 Financial 0

latest quarter score

Earnings Reports

8
MiNK Therapeutics (INKT) Q2 2026: Randomized Phase 2 Trial Launch and $8.8M Cash Support Clinical Execution
August 18, 2026
10
Mink Therapeutics (INKT) Q1 2026: 90-Patient ARDS Trial Launch Signals Pivotal Data Path
May 15, 2026
10
Mink Therapeutics (INKT) Q4 2025: Operating Costs Down 40% as Pipeline Advances to Randomized Trials
March 31, 2026
9
Mink Therapeutics (INKT) Q3 2025: 700% Equity Surge Fuels Pipeline Expansion in INKT Cell Therapy
November 14, 2025
9
Mink Therapeutics (INKT) Q2 2025: 30% Burn Reduction Extends Runway as INKT Platform Delivers Durable Responses
August 14, 2025
9
MiNK Therapeutics (INKT) Q1 2025: Clinical Milestones Drive Strategic Partnerships and Capital Efficiency
May 15, 2025
9
MiNK Therapeutics (INKT) Q4 2024: Net Loss Halves Amid Clinical and Strategic Momentum
March 18, 2025

Browse all companies